A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions
Lipoma
Interventions
DRUG

Collagenase Clostridium Histolyticum

This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Trial Locations (1)

11557

Zachary E. Gerut, M.D., Hewlett

All Listed Sponsors
collaborator

Advance Biofactures Corporation

INDUSTRY

lead

Zachary Gerut

INDIV

NCT01613313 - A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | Biotech Hunter | Biotech Hunter